Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors
Authors
Gyurkocza, BoglarkaPlescia, Janet
Raskett, Christopher M.
Garlick, David S.
Lowry, Philip A.
Carter, Bing Z.
Andreeff, Michael
Meli, Massimiliano
Colombo, Giorgio
Altieri, Dario C.
UMass Chan Affiliations
Department of Cancer Biology and Cancer CenterDocument Type
Journal ArticlePublication Date
2006-08-03Keywords
Acute DiseaseAnimals
Antineoplastic Agents
Apoptosis
Blotting, Western
Cell Line, Tumor
Cell Survival
Disease Models, Animal
Enzyme-Linked Immunosorbent Assay
Female
Glycine
HL-60 Cells
HSP90 Heat-Shock Proteins
Humans
K562 Cells
Leukemia, Myeloid
Lysine
Male
Mice
Mice, SCID
Microscopy, Fluorescence
Microtubule-Associated Proteins
Neoplasm Proteins
Peptide Fragments
Research Design
Transplantation, Heterologous
U937 Cells
Life Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
BACKGROUND: Heat shock protein 90 (Hsp90) is a molecular chaperone that is involved in signaling pathways for cell proliferation, survival, and cellular adaptation. Inhibitors of Hsp90 are being examined as cancer therapeutic agents, but the molecular mechanism of their anticancer activity is still unclear. We investigated Hsp90 as a therapeutic target for acute myeloid leukemia (AML) by use of the Hsp90 inhibitor shepherdin (a novel peptidyl antagonist of the interaction between Hsp90 and survivin, which is a regulator of cell proliferation and cell viability in cancer). METHODS: We studied protein interactions by molecular dynamics simulations and conducted competition experiments by use of enzyme-linked immunosorbent assay (ELISA). Shepherdin[79-83], a novel variant carrying the survivin sequence from Lys-79 through Gly-83, or its scrambled peptide was made permeable to cells by adding the antennapedia helix III carrier sequence. Apoptosis, Hsp90 client protein expression, and mitochondrial dysfunction were evaluated in AML types (myeloblastic, monocytic, and chronic myelogenous leukemia in blast crisis), patient-derived blasts, and normal mononuclear cells. Effects of shepherdin on tumor growth were evaluated in AML xenograft tumors in mice (n = 6). Organ tissues were examined histologically. RESULTS: Shepherdin[79-83] bound to Hsp90, inhibited formation of the survivin-Hsp90 complex, and competed with ATP binding to Hsp90. Cell-permeable shepherdin[79-83] induced rapid (within 30 minutes) and complete (with concentrations inducing 50% cell death of 24-35 microM) killing of AML types and blasts, but it did not affect normal mononuclear cells. Shepherdin[79-83] made contact with unique residues in the ATP pocket of Hsp90 (Ile-96, Asp-102, and Phe-138), did not increase Hsp70 levels in AML cells, disrupted mitochondrial function within 2 minutes of treatment, and eliminated the expression of Hsp90 client proteins. Shepherdin[79-83] abolished growth of AML xenograft tumors (mean of control group = 1698 mm3 and mean of treated group = 232 mm3; difference = 1466 mm3, 95% confidence interval = 505.8 to 2426; P = .008) without systemic or organ toxicity and inhibited Hsp90 function in vivo. CONCLUSIONS: Shepherdin is a novel Hsp90 inhibitor with a unique mechanism of anticancer activity.Source
J Natl Cancer Inst. 2006 Aug 2;98(15):1068-77. Link to article on publisher's siteDOI
10.1093/jnci/djj300Permanent Link to this Item
http://hdl.handle.net/20.500.14038/38286PubMed ID
16882944Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1093/jnci/djj300